Strategic collaboration with leading global manufacturer of drug delivery systems strengthens NS002's clinical and commercial roadmap with end-to-end development support and manufacturing infrastructureTEL AVIV, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the execution of comprehensive agreements wi ...

Core Insights - Nasus Pharma Ltd. has successfully listed on the New York Stock Exchange and celebrated this milestone by ringing the Closing Bell on August 25, 2025, highlighting its commitment to transforming emergency medicine through innovative intranasal therapies [1][2][3] Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products aimed at treating acute medical conditions, particularly severe allergic reactions and anaphylaxis [4] - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine, designed as a needle-free alternative to traditional Epinephrine autoinjectors [4] Technology and Innovation - The proprietary powder-based intranasal (PBI) technology developed by Nasus Pharma is intended for rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [4] - The PBI formulation employs uniform spherical powder particles to ensure broad dispersion and potentially faster absorption compared to liquid-based nasal products [4] Leadership and Vision - The CEO of Nasus Pharma, Dan Teleman, emphasized the company's dedication to innovation and its mission to develop life-saving treatments that are easy to use and accessible during emergencies [3]